Skip to content


  • Review
  • Open Access

Genotype-phenotype correlations of amyotrophic lateral sclerosis

Translational Neurodegeneration20165:3

  • Received: 1 July 2015
  • Accepted: 27 January 2016
  • Published:


Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive neuronal loss and degeneration of upper motor neuron (UMN) and lower motor neuron (LMN). The clinical presentations of ALS are heterogeneous and there is no single test or procedure to establish the diagnosis of ALS. Most cases are diagnosed based on symptoms, physical signs, progression, EMG, and tests to exclude the overlapping conditions. Familial ALS represents about 5 ~ 10 % of ALS cases, whereas the vast majority of patients are sporadic. To date, more than 20 causative genes have been identified in hereditary ALS. Detecting the pathogenic mutations or risk variants for each ALS individual is challenging. However, ALS patients carrying some specific mutations or variant may exhibit subtly distinct clinical features. Unraveling the respective genotype-phenotype correlation has important implications for the genetic explanations. In this review, we will delineate the clinical features of ALS, outline the major ALS-related genes, and summarize the possible genotype-phenotype correlations of ALS.


  • Amyotrophic lateral sclerosis
  • Diagnosis of ALS
  • Causative genes
  • Genetic explanations
  • Genotype-phenotype correlations


Amyotrophic lateral sclerosis (ALS) is a devastating and inexorable neurodegenerative disease characterized by progressive neuronal loss and degeneration of upper motor neuron (UMN) and lower motor neuron (LMN) [1]. It is the most widespread type of motor neuron disease and has become the third most common neurodegenerative disease in the world [2]. Patients affected with ALS typically suffer from progressive muscle weakness and atrophy and usually die from respiratory failure 2 to 3 years after the onset [3]. ALS is a relentless and incurable disease. There has been no effective therapeutic approach to halt the progression so far. ALS is heterogeneous in its presentation, course, and progression. No single test for diagnosing ALS exists; most cases are diagnosed based on symptoms, physical signs, progression, EMG, and tests to exclude the overlapping conditions.

The etiology of ALS is not fully understood. Appropriate 5 ~ 10 % of ALS is familial (FALS) with a Mendelian pattern of inheritance, suggesting that genetic factors play important roles in the pathogenesis of ALS [4]. To date, more than 20 causative genes have been identified in hereditary ALS. In addition, about 30 potential causative or disease-modifying genes have also been identified. Detecting the pathogenic mutations or risk variants for each ALS individual is therefore challenging. Clinical features do not reliably separate the hereditary ALS from sporadic ALS (SALS) due to phenotypic overlap. However, ALS patients carrying some specific mutations may exhibit subtly distinct clinical features. Unraveling the genotype-phenotype correlations has important implications for the genetic explanations. In this review, we will delineate the clinical features of ALS, outline the major ALS-related genes, and review the possible genotype-phenotype correlations. We hope this review will be in favor of improving the accuracy of genetic screenings.

Clinical features of ALS

ALS usually commences in later life, with a mean age at onset (AAO) of 65 year. The onset for FALS tends to be earlier than that of SALS. A small proportion of patients may developed juvenile ALS (JALS), in which onset occurs in the first two decades [5]. Symptoms usually begin in the limbs (termed limb onset), although approximate 25 % of ALS patients have bulbar onset. Associated with poorer prognosis, bulbar onset is more common in elderly patients and women [6]. Upper limb weakness and atrophy at onset are most common, subsequently spreading to involve bulbar, trunk, or respiratory muscle [7]. After initial presentation of symptoms, the disease progresses to include both UMN and LMN symptoms and signs. The UMN disturbance involving limbs leads to spasticity, weakness, and brisk reflexes. The LMN features of limbs comprise muscle atrophy, weakness, fasciculation, and decreased reflexes. As limb function deteriorates, patients gradually lose their ability to walk. Bulbar UMN dysfunction includes spastic dysarthria and brisk jerk of gag and jaw, while bulbar LMN dysfunction includes tongue wasting, weakness, and fasciculation. In the later stage of ALS, most cases develop dysphagia, which are associated with weight loss and malnutrition.

Sensory loss is usually absent, but cognitive impairment is common in ALS cases. A significant proportion of ALS cases develop cognitive dysfunction, and in a minority, overt dementia [7]. With appropriate cognitive assessment, 20 ~ 50 % of patients with ALS fulfill the consensus criteria for probable or definite frontal temporal dementia (FTD) [8]. In addition, about 30 % of FTD patients manifest signs of motor system dysfunction [9]. The occurrence of ALS, FTD, or ALS with FTD in intra-familial members discloses a considerable overlap between ALS and FTD.

Causative genes

Since the identification of first causative gene in 1993, a growing number of ALS-causing genes associated with Mendelian inheritance have been identified. Although FALS represents only 5 ~ 10 % of ALS cases, investigations of the causative genes have greatly increased our understanding of the etiology of ALS. FALS is generally inherited in an autosomal dominant pattern and rarely inherited as an autosomal recessive or X-linked trait [10]. Adult onset autosomal dominant inheritance is more common than juvenile onset which is usually caused by recessive transmission.

To date, at least 21 chromosomal regions containing 19 identified genes have been linked to ALS, termed as ALS 1–21 respectively (Table 1). In 2011, the chromosome 9 open reading frame 72 (C9ORF72) repeat expansions were identified in a significant proportion of ALS and FTD patients, becoming the most common genetic cause of ALS in the Caucasian population. There has been strong evidence to support the pathogenic role for mutations in Cu/Zn superoxide dismutase 1 (SOD1), Fused in sarcoma (FUS), TAR DNA-binding protein (TARDBP), and C9ORF72. However, mutations in other genes are not common or even rarely seen in ALS cases. In addition to the aforementioned ALS genes, a constellation of other genes have also been implicated in ALS [11]. But mutations in these genes are only identified in a small fraction of ALS patients, indicating that these mutated genes have little contribution to the development of ALS.
Table 1

Different subtypes of familial ALS and their genotype–phenotype correlations

ALS type



ALS features


Other features/disorders





AAO: adult > juvenile; Onset: LL > UL > bulbar;


PMA, PBP, BFA, cerebellar ataxia, autonomic dysfunction


De novo

Progression: rapid > slow; UMN + LMN > LMN dominant




AAO: juvenile; Onset: LL, UL;




Progression: slow; UMN dominant > UMN + LMN











AAO: juvenile > adult; Onset: LL > UL;


AOA2, cerebellar ataxia, motor neuropathy


Progression: slow; UMN + LMN > LMN dominant




AAO: juvenile > adult; Onset: bulbar, limb;


HSP, autonomic dysfunction, mental retardation


Progression: slow; UMN dominant > UMN + LMN




AAO: adult > juvenile; Onset: UL, bulbar > LL;


PMA, Parkinsonism, essential tremor, mental retardation


De novo

Progression: rapid > slow; UMN + LMN > LMN dominant











AAO: adult > juvenile; Onset: limb;


SMA, motor neuropathy, autonomic dysfunction


Progression: slow; LMN dominant




AAO: adult > juvenile; Onset: limb, bulbar;




Progression: N/A; UMN + LMN

ALS 10



AAO: adult; Onset: limb, bulbar;


PSP, FTD with Parkinsonism, PD, chorea


Progression: variable; UMN + LMN

ALS 11



AAO: adult; Onset: bulbar > limb;


CMT4J, HSP, PLS, Yunis–Varon syndrome, epilepsy with polymicrogyria


Progression: variable; UMN + LMN > UMN dominant

ALS 12



AAO: adult; Onset: bulbar, limb;


POAG, Parkinsonism, aphasia


Progression: slow; UMN + LMN

ALS 13



AAO: adult > juvenile; Onset: UL, LL;


SCA2, Parkinsonism


Progression: variable; UMN + LMN

ALS 14



AAO: adult > juvenile; Onset: limb > bulbar;




Progression: variable; UMN + LMN

ALS 15



AAO: adult > juvenile; Onset: limb, bulbar;




Progression: variable; UMN + LMN > UMN dominant

ALS 16



AAO: juvenile; Onset: LL > UL;


motor neuropathy


Progression: N/A; UMN + LMN

ALS 17



AAO: adult; Onset: bulbar, limb;


PMA; Parkinsonism


Progression: N/A; UMN + LMN > LMN dominant

ALS 18



AAO: adult; Onset: limb;




Progression: N/A; UMN + LMN

ALS 19



AAO: adult; Onset: UL, bulbar;




Progression: slow; UMN + LMN

ALS 20



AAO: adult; Onset: N/A;


multisystem proteinopathy


Progression: N/A; UMN + LMN > LMN dominant

ALS 21



AAO: adult; Onset: bulbar, limb;


distal myopathy


Progression: slow; UMN + LMN > LMN dominant




AAO: adult; Onset: bulbar, limb;


Parkinsonism, cerebellar ataxia


Progression: rapid > slow; UMN + LMN

Abbreviations: AAO age at onset, AD autosomal dominant, ALS amyotrophic lateral sclerosis, AOA2 ataxia and oculomotor apraxia type 2, AR autosomal recessive, BFA benign focal amyotrophy, CMT4J Charcot-Marie-Tooth disease, FTD frontotemporal dementia, HSP hereditary spastic paraplegia, IAHSP infantile-onset ascending hereditary spastic paralysis, IBMPFD inclusion body myopathy with Paget’s disease and frontotemporal dementia, LL lower limb, LMN lower motor neuron, N/A not available, PBP progressive bulbar palsy, PD Parkinson’s disease, PLS primary lateral sclerosis, PMA progressive muscular atrophy, POAG primary open angle glaucoma, PSP progressive supranuclear palsy, SCA2 spinocerebellar ataxia 2, UL upper limb, UMN upper motor neuron; UN unknown, XD X-linked dominant

Genotype-phenotype correlations


The first causative gene of ALS was identified as SOD1 in 1993 [12]. Mutations in SOD1 are very common, accounting for about 20 % of FALS and 1 ~ 2 % SALS cases [13]. To date, more than 185 disease-associated mutations have been described, spread throughout all the 5 exons of SOD1 [14]. The majority of SOD1 mutations are missense mutations, while small deletions or insertions are also described [15]. The pattern of inheritance is autosomal dominant except for the p.D90A mutation which is recessive in the Scandinavian population and dominant in others [16]. Among the SOD1 mutations, p.D90A is the most common worldwide. However, regional disparity of SOD1 mutations also exists. For example, the most frequent SOD1 mutation in North America is p.A4V [17], but in the UK and Japan, the most common mutations are p.I113T, and p.H46R, respectively [18].

Overall, most patients with SOD1 mutations develop a rapidly progressive ALS, although some cases show a diverse phenotype. AAO and severity may vary significantly depending on the variants involved. Patients with p.A4V, p.H43R, p.L84V, p.G85R, p.N86S, or p.G93A mutations exhibit an aggressive form of ALS with survival shorter than 3 years, while cases with p.G93C, p.D90A, or p.H46R mutations show longer life expectancies [18]. Cognitive impairment is very rare and bulbar onset is less frequent than in other FALS types [19]. Some cases with SOD1 mutations have distinct clinical features. Patients carrying homozygous p.D90A mutation manifest insidious onset and a slow progression of ALS, with bladder involvement at the later stage [20]. In contrast, heterozygous p.D90A mutation is associated with various forms of ALS, including bulbar onset, upper-limb onset and fast progression, and lower-limb onset with fast progression [21, 22]. The p.A4V mutation causes a limb-onset aggressive form of ALS, with survival less than 2 years after the onset [23]. Cases with p.A4T mutation have a similar phenotype to that seen in p.A4V mutation [24]. We previously reported SOD1 p.C111Y and p.G147D mutations in 3 Chinese ALS families. The p.C111Y mutation led to a relatively mild ALS phenotype, while the p.G147D was associated with a rapid progressive ALS [25]. The recently reported novel p.R115C mutation was identified in an ALS patient who had an extremely rapid progression and aggressive phenotype [14]. Another novel p.T137A mutation identified in two unrelated Italian families, however, causes a very slow progression of ALS [26, 27].

ALS2: Alsin

Mutations in ALS2 are responsible for autosomal recessive, early-onset forms of upper motor neuron diseases, such as infantile ascending hereditary spastic paraplegia (IAHSP) and juvenile primary lateral sclerosis (PLS) [28, 29]. To date, more than 50 patients with early onset (~1 year) of the disease have been reported to harbor Alsin mutations [18]. In the typical adult onset ALS, Alsin gene is rarely mutated [30]. Recently, a novel splice-site mutation (c.3512 + 1G > A) in Alsin was identified in a consanguineous JALS family with early onset anarthria and generalized dystonia [31].

ALS4: senataxin (SETX)

ALS4 is a rare autosomal dominant form of juvenile-onset ALS due to mutations in SETX [32]. It is characterized by slowly evolving distal muscle weakness and atrophy, pyramidal signs, and sparing of bulbar and respiratory muscles [33]. In some cases, normal lifespan or atypical features are also described [34, 35]. A patient with SETX p.R2136C mutation presented with coexistence of ALS and inflammatory radiculoneuropathy [36]. We previously reported a missense mutation p.T1118I in a sporadic Chinese ALS patient who developed bulbar symptoms 3 years after the onset, and respiratory failure 2 years later [37]. In addition, recessive SETX mutations are reported to cause ataxia and oculomotor apraxia type 2 (AOA2) [38, 39].

ALS5: spatacsin (SPG11)

SPG11 mutations were recently identified in several juvenile-onset ALS cases, with autosomal recessive inheritance and AAO ranging from 7 to 23 years [18, 40]. Generally, the SPG11-associated ALS showed a slow progression and in some cases apparent UMN involvement [41]. In addition to ALS phenotype, mutations in SPG11 also cause hereditary spastic paraplegia (HSP) with thin corpus callosum [42].


Mutations in FUS gene have emerged as the second most common cause of ALS, accounting for about 3 ~ 5 % FALS and ~1 % SALS [43, 44]. Up to now, more than 60 mutations in FUS have been identified in ALS cases (, accessed in March, 2015). Among these mutations, the majority are clustered in exon 15 which encode the C-terminus of the protein, and the most common one is p.R521C [15]. The inheritance is autosomal dominant aside from an autosomal recessive p.H517Q mutation and several de novo mutations [44].

The phenotypes associated with FUS mutations include adult-onset ALS, JALS, ALS-FTD, and rarely pure FTD [45]. Although most patients carrying FUS mutations exhibit a classical ALS phenotype without cognitive impairment, the clinical course of these ALS cases are diverse, even among carriers of the same mutations. Compared to SOD1 patients, FUS-related ALS have an earlier AAO, more frequent bulbar disease, and a more rapid progression [46]. Some FUS mutations are also observed in patients with juvenile-onset ALS with AAO younger than 25 years [47, 48]. Atypical features such as ALS with mental retardation, ALS with parkinsonism and dementia [46], and essential tremor were seen in some patients with FUS mutations [49].

ALS8: vesicle associated membrane protein B (VAPB)

VAPB mutation was firstly described in several Brazilian families with motor neuron degeneration of various patterns: late-onset spinal muscular atrophy, atypical ALS, or typical ALS [50]. Subsequently, five other point mutations and a small deletion were described. Overall, VAPB mutations are extremely rare in FALS. The phenotype-genotype correlation remains largely undetermined so far.

ALS9: angiogenin (ANG)

The role of ANG mutations in ALS remains ambiguous. Approximate 30 ANG mutations have been reported in ALS, but only the p.K17II mutation is shown to co-segregate with the disease [51]. Mutations in ANG account for a small fraction of ALS cases. A few FALS cases are identified to have concomitant ANG mutations with FUS [52] or SOD1 [53] mutations. In addition, some ANG mutations are detected in healthy controls [54]. A subset of ANG mutation carriers showed cognitive impairment suggestive of FTD [55], or Parkinson’s disease (PD) [56].


Mutations in TARDBP encoding TDP-43 account for 4 % of FALS cases and ~1 % of SALS [57, 58]. More than 50 mutations have been identified so far (, accessed in March, 2015), mostly clustered in the C-terminal region encoded by exon 6 of TARDBP. Mutations in TARDBP are predominantly missense with an autosomal dominant inheritance. Although TARDBP mutations are detected in ALS cases worldwide, some regional diversity does exist. For instance, the p.A382T mutation has been found in 28.7 % of all ALS cases in Sardinia [59].

Patients with TARDBP mutations usually exhibit a typical ALS phenotype, with limb or bulbar onset, variable disease course, and no overt dementia [60]. It is reported that the TARDBP–linked ALS has a trend for earlier AAO, more upper limb onset, and a longer duration, compared to SALS patients [52, 61]. However, we previously reported a TARDBP p.S292N mutation in a FALS case who developed dysarthria, dysphagia, and atrophy of lingual muscle at the age of 64 years [62]. The progression of ALS in this case seemed to be rapid. Other phenotypes associated with TARDBP mutations include FTD [63], ALS-FTD [64], ALS with extrapyramidal signs [65], FTD with parkinsonism [66], and PD [67].

ALS11: factor induced gene 4 (FIG4)

FIG4 was previously implicated in Charcot-Marie-Tooth disease type 4J (CMT4J) [68]. Later, FIG4 mutations were found in autosomal dominant FALS and SALS cases [69]. However, ALS was a rare phenotype of FIG4 gene. The other phenotypes associated with FIG4 mutations include PLS [69], Yunis–Varon syndrome [70], and familial epilepsy with polymicrogyria [71].

ALS12: optineurin (OPTN)

Previously identified as the cause of primary open angle glaucoma (POAG) [72], mutations in OPTN have been found in both FALS and SALS cases in either a dominant or recessive manner [73]. Although OPTN mutations are relatively common in Japan ALS cases [73, 74], they are rare in Caucasian patients [75, 76]. The OPTN-related ALS showed relatively slow progression and long duration before respiratory dysfunction [73]. In addition to ALS phenotype, some patients with OPTN mutations present with extrapyramidal symptoms, aphasia, or FTD [77, 78].

ALS13: Ataxin-2 (ATXN2)

Long (more than 33) CAG repeat expansion in ATXN2 gene has been identified as a cause of spinocerebellar ataxia type 2 (SCA2) [79]. Recent studies demonstrated that intermediate expansion (27 ~ 33 repeats) of ATXN2 was a significant risk factor for ALS [8082]. However, whether the clinical features of ALS can be affected by ATXN2 intermediate repeats is still controversial, because no correlation between ATXN2 repeat length and AAO or survival was observed [83]. A few case reports have described motor neuron degeneration in SCA2 families, raising the possibility that motor neuron involvement is part of SCA2 [84, 85].

ALS14: Valosin-containing protein (VCP)

The gene of VCP is known to be mutated in inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD) [86]. Recently, mutations in VCP were identified in patients with FALS or SALS [87]. Actually, VCP mutations are not a major cause of ALS. Although more than 38 mutations in VCP have been discovered (, accessed in March, 2015), only a few of them are responsible for ALS. The phenotype of patients with VCP mutations shows intra-familial variations from IBMPFD to FALS [88], or from ALS to FTD or ALS-FTD [87].

ALS15: ubiquilin 2 (UBQLN2)

Mutations in UBQLN2 were recently identified in X-linked dominant FALS [89]. However, UBQLN2 mutations are not a frequent cause of ALS [90]. In the affected cases, incomplete penetrance has been noted in females [89]. The predominant phenotype associated with UBQLN2 mutations is ALS, although several patients have concomitant symptoms of FTD [10]. The AAO has been reported to be significantly younger in males than in females, presumably because males are hemizygous but females are heterozygous for the mutation [89].

ALS16: sigma non-opioid intracellular receptor 1 (SIGMAR1)

SIGMAR1 mutations were recently identified in families affected with juvenile ALS [91] or ALS with dementia [92]. However, these findings have not been replicated by other groups, suggesting that SIGMAR1 is a rare causative gene of ALS. Recently a splice-site mutation (c.151 + 1G > T) in SIGMAR1 was reported to cause autosomal recessive distal hereditary motor neuropathy in a consanguineous Chinese family [93].

ALS17: chromatin modifying protein 2B (CHMP2B)

Mutations in the CHMP2B gene were initially identified in patients with FTD [94] and then identified in patients with ALS [95, 96]. Since only several ALS cases with CHMP2B mutations were reported, there was no characteristic ALS clinical subtype associated with these patients. In addition, CHMP2B mutation (p.R69Q) was also identified in progressive muscular atrophy (PMA) [96].

ALS18: profilin 1 (PFN1)

Missense mutations in PFN1 are firstly reported in two large ALS families and 7 FALS patients [97]. Later, screenings of sizeable ALS and FTD cohorts from diverse populations demonstrated that PFN1 mutations are a rare cause of ALS [98100]. The reported cases with PFN1 mutations seem to present classical ALS with limb onset and no evidence of FTD [97, 99, 101].

ALS19: erb-b2 receptor tyrosine kinase 4 (ERBB4)

Recently, ERBB4 was identified a causative gene of FALS19, which was characterized by typical, slowly progressive ALS and a lack of obvious cognitive dysfunction [102]. However, this finding has not been replicated by other groups. The genotype-phenotype correlations are thus not determined.

ALS20: heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)

Mutations in hnRNPA1 gene were recently identified in patients presenting with ALS and/or multisystem proteinopathy (MSP) [103]. However, subsequent studies failed to identify hnRNPA1 mutations in patients with ALS, FTD, or MSP [103105]. The associations of ALS with hnRNPA1 mutations are still controversial.

ALS21: matrin-3 (MATR3)

Several mutations in MATR3 were recently reported to cause ALS [106]. Later, a heterozygous MATR3 p.A72T mutation was identified in a sporadic ALS patient with bulbar onset [107]. In another study, 2 splicing variants and a missense mutation were identified in 3 ALS cases with AAO ranging from 58 to 79 years, and bulbar onset in 2 cases [108].


In 2011, two independent groups reported that the massive GGGGCC hexanucleotide repeat expansion in the non-coding regions of C9ORF72 gene caused chromosome 9p-linked ALS and FTD [109, 110]. Currently, C9ORF72 repeat expansions have become the most frequently genetic cause of FALS and familial FTD, accounting for about 40 and 25 % of the cases, respectively [13]. In families with ALS-FTD, the frequency reaches to 50–72 % [19]. Notwithstanding, the mutations seem to be geographically clustered, accounting for one third of FALS cases in Europe and North America, but a small percentage in Asian populations. Haplotype analysis indicates that a common European founder appears to be responsible for all cases [111].

The C9ORF72 repeat expansions are associated with various phenotypes, including typical ALS, PMA, PLS, ALS-FTD, and pure FTD [44]. In patients with C9ORF72 mutations, bulbar onset and cognitive impairment seems to be more frequent, and median survival is relatively lower than in patients carrying TARDBP or SOD1 mutations [19]. However, there is no association between the repeat length and disease phenotype or AAO in C9ORF72 mutation carriers [112]. In addition, the C9ORF72 expansions also underlie a small portion of other neurological diseases, such as Alzheimer’s disease (AD) [113], Huntington’s disease (HD) [114], and PD [115].

Other genes implicated in ALS

Several other genes are also implicated in ALS. DCTN1 mutations were first identified in a family affected with LMN disease [116] and soon identified in several ALS families [117, 118]. Subsequently, a cluster of DCTN1 mutations were identified in pedigrees with Perry syndrome [119], PD [120] or progressive supranuclear paralysis (PSP) [121], suggestive of phenotypic variability of DCTN1 mutations. Mutations in SQSTM1 were initially identified as a cause of Paget disease of bone (PDB) [122]. Recently, SQSTM1 mutations were identified in ALS [123, 124] as well as FTD [125]. It is speculated that SQSTM1 mutations are mainly associated with late-onset SALS, because the number of early-onset patients with SQSTM1 mutations is much less than that of late-onset patients with SQSTM1 mutations [126].

In addition, mutations in several other genes such as DAO, UNC13A, NEFH, PRPH, TAF15, and ELP3, have been reported as rare causes of ALS. For some genes, there are no additional reports about the mutations as a cause of ALS since the initial publications. Therefore, the evidence supporting a causative role of ALS is not fully convincing.

Implication of the genotype-phenotype correlations

There is no a standard procedure to test the causative mutation in cases with ALS. Many factors should be considered, such as AAO, clinical features, progression, FTD involvement, inheritance manner, and even ethnicity. In this review, we summarized the possible genotype-phenotype correlations of ALS with the aim of providing some clue to improve the clinical decision. Here, we provided a flow diagram of genetic screening strategy in cases diagnosed with ALS (Fig. 1). AAO is an importance factor for the genetic investigations and can be divided into juvenile onset and adult onset. Juvenile onset is usually present in ALS1, ALS2, ALS4, ALS5, ALS6, ALS8, ALS9, ALS13, ALS15, and ALS16. For these cases with juvenile onset and UMN dominant symptoms, Alsin, SPG11, SIGMAR1, or UBQLN2 might be a causative gene. In contrast, FUS, VAPB, SOD1, and SETX should be considered in cases with juvenile onset and LMN dominant phenotype. For these cases with juvenile onset and FTD symptoms, ANG, UBQLN2, and SIGMAR1 can be investigated. In addition, SPG11 and FUS can be sequenced in cases who also present mental retardation, while SOD1, Alsin, SETX, ATXN2 can be considered in those cases with coexistence of cerebellar ataxia.

Fig. 1
Fig. 1

A flow diagram of genetic screening strategy in cases diagnosed with ALS

In cases with adult-onset ALS, many genes should be considered. Although the majority exhibit typical ALS features with both UMN and LMN symptoms, a fraction of cases present either UMN dominant symptoms or LMN dominant symptoms. SPG11, FIG4, UBQLN2 may be mutated in cases with UMN dominant symptoms. In these cases with LMN dominant symptoms, mutations in SOD1, SETX, FUS, VAPB, VCP, CHMP2B, hnRNPA1, or MATR3 might be identified. Presence of FTD hints possible mutations in ANG, TARDBP, OPTN, VCP, UBQLN2, CHMP2B, hnRNPA1, MATR3, or C9ORF72. Motor neuropathy involvement might occur in cases with mutations in SETX, VAPB, or FIG4. Complications of ataxia may be seen in cases with SOD1 or ATXN2 mutations.

Inheritance pattern also provides critical information as to the potential involvement of one or other specific genes in ALS. However, the diverse clinical features between intra-familial cases or a deceased parent at a young age may results in the appearance of “lack of familial history” in some cases. The presentation of ALS or FTD in first-degree relatives and the co-occurrence of ALS with FTD in some patients with ALS supported a positive family history. In addition, ethnic background should be considered when determining which genes are most likely. For example, C9ORF72 has been regarded as the most common cause of ALS in Caucasians, but very rare in Asian population.


Here, we outline the genotype-phenotype correlations of ALS. We hope this review is helpful for detecting the causative mutation in cases with ALS. Although a number of genes have been reported, many ALS cases still do not carry any mutation in the aforementioned genes. Other more genes might be identified as causative genes of ALS in the future.



age at onset


Alzheimer’s disease


amyotrophic lateral sclerosis




oculomotor apraxia type 2




chromosome 9 open reading frame 72


Charcot-Marie-Tooth disease




erb-b2 receptor tyrosine kinase 4


familial amyotrophic lateral sclerosis


factor induced gene 4


frontal temporal dementia


fused in sarcoma


Huntington’s disease


heterogeneous nuclear ribonucleoprotein A1


hereditary spastic paraplegia


infantile-onset ascending hereditary spastic paralysis


inclusion body myopathy with Paget disease of bone and frontotemporal dementia


juvenile amyotrophic lateral sclerosis


lower motor neuron




multisystem proteinopathy




Parkinson’s disease


Paget disease of bone


profilin 1


juvenile primary lateral sclerosis


progressive muscular atrophy


progressive supranuclear paralysis


sporadic amyotrophic lateral sclerosis


spinocerebellar ataxia




sigma non-opioid intracellular receptor 1


superoxide dismutase 1




sequestosome 1


TAR DNA-binding protein


ubiquilin 2


upper motor neuron


vesicle associated membrane protein B



This work was supported by grants from the National Natural Science Foundation to Zhi-Ying Wu (81125009, Beijing).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and the Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, 88 Jiefang Rd, Hangzhou, 310009, China


  1. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.PubMed CentralPubMedView ArticleGoogle Scholar
  2. Sathasivam S. Motor neurone disease: clinical features, diagnosis, diagnostic pitfalls and prognostic markers. Singapore Med J. 2010;51:367–72. quiz 73.PubMedGoogle Scholar
  3. Finsterer J, Burgunder JM. Recent progress in the genetics of motor neuron disease. Eur J Med Genet. 2014;57:103–12.PubMedView ArticleGoogle Scholar
  4. Forbes RB, Colville S, Swingler RJ. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing. 2004;33:131–4.PubMedView ArticleGoogle Scholar
  5. Gouveia LO, de Carvalho M. Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity? Amyotroph Lateral Scler. 2007;8:323–7.PubMedView ArticleGoogle Scholar
  6. McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med. 2010;7:557–70.PubMedView ArticleGoogle Scholar
  7. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.PubMedView ArticleGoogle Scholar
  8. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586–90.PubMedView ArticleGoogle Scholar
  9. Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134:2582–94.PubMedView ArticleGoogle Scholar
  10. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17–23.PubMed CentralPubMedView ArticleGoogle Scholar
  11. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.PubMedView ArticleGoogle Scholar
  12. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science. 1993;261:1047–51.PubMedView ArticleGoogle Scholar
  13. Baumer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc Med. 2014;107:14–21.PubMedView ArticleGoogle Scholar
  14. Tortelli R, Conforti FL, Cortese R, D’Errico E, Distaso E, Mazzei R, et al. Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene. Neurobiol Aging. 2013;1709(34):e3–5.Google Scholar
  15. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nature reviews. Neurology. 2011;7:603–15.PubMedGoogle Scholar
  16. Jonsson PA, Backstrand A, Andersen PM, Jacobsson J, Parton M, Shaw C, et al. CuZn-superoxide dismutase in D90A heterozygotes from recessive and dominant ALS pedigrees. Neurobiol Dis. 2002;10:327–33.PubMedView ArticleGoogle Scholar
  17. Saeed M, Yang Y, Deng HX, Hung WY, Siddique N, Dellefave L, et al. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72:1634–9.PubMed CentralPubMedView ArticleGoogle Scholar
  18. Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl Neurodegener. 2015;4:13.PubMed CentralPubMedView ArticleGoogle Scholar
  19. Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet. 2013;83:408–16.PubMedView ArticleGoogle Scholar
  20. Andersen PM, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, Keranen ML, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain. 1996;119(Pt 4):1153–72.PubMedView ArticleGoogle Scholar
  21. Parton MJ, Broom W, Andersen PM, Al-Chalabi A, Nigel Leigh P, Powell JF, et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype. Hum Mutat. 2002;20:473.PubMedView ArticleGoogle Scholar
  22. Robberecht W, Aguirre T, Van den Bosch L, Tilkin P, Cassiman JJ, Matthijs G. D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. Neurology. 1996;47:1336–9.PubMedView ArticleGoogle Scholar
  23. Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu, Zn superoxide dismutase. Neurology. 1997;48:55–7.PubMedView ArticleGoogle Scholar
  24. Aksoy H, Dean G, Elian M, Deng HX, Deng G, Juneja T, et al. A4T mutation in the SOD1 gene causing familial amyotrophic lateral sclerosis. Neuroepidemiology. 2003;22:235–8.PubMedView ArticleGoogle Scholar
  25. Niu YF, Xiong HL, Wu JJ, Chen Y, Qiao K, Wu ZY. [Screening of mutations in SOD1 gene and analysis of genotype-phenotype correlation in Chinese patients with amyotrophic lateral sclerosis]. Yi chuan = Hereditas / Zhongguo yi chuan xue hui bian ji. 2011;33:720–4.PubMedView ArticleGoogle Scholar
  26. Origone P, Caponnetto C, Verdiani S, Mantero V, Cichero E, Fossa P, et al. T137A variant is a pathogenetic SOD1 mutation associated with a slowly progressive ALS phenotype. Amyotroph Lateral Scler. 2012;13:398–9.PubMedView ArticleGoogle Scholar
  27. Visani M, de Biase D, Bartolomei I, Plasmati R, Morandi L, Cenacchi G, et al. A novel T137A SOD1 mutation in an Italian family with two subjects affected by amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:385–8.PubMedView ArticleGoogle Scholar
  28. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 2001;29:166–73.PubMedView ArticleGoogle Scholar
  29. Eymard-Pierre E, Lesca G, Dollet S, Santorelli FM, di Capua M, Bertini E, et al. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet. 2002;71:518–27.PubMed CentralPubMedView ArticleGoogle Scholar
  30. Hand CK, Devon RS, Gros-Louis F, Rochefort D, Khoris J, Meininger V, et al. Mutation screening of the ALS2 gene in sporadic and familial amyotrophic lateral sclerosis. Arch Neurol. 2003;60:1768–71.PubMedView ArticleGoogle Scholar
  31. Siddiqi S, Foo JN, Vu A, Azim S, Silver DL, Mansoor A, et al. A novel splice-site mutation in ALS2 establishes the diagnosis of juvenile amyotrophic lateral sclerosis in a family with early onset anarthria and generalized dystonias. PLoS One. 2014;9:e113258.PubMed CentralPubMedView ArticleGoogle Scholar
  32. Chen YZ, Bennett CL, Huynh HM, Blair IP, Puls I, Irobi J, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74:1128–35.PubMed CentralPubMedView ArticleGoogle Scholar
  33. Hirano M, Quinzii CM, Mitsumoto H, Hays AP, Roberts JK, Richard P, et al. Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:223–7.PubMedView ArticleGoogle Scholar
  34. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710–23.PubMedView ArticleGoogle Scholar
  35. Rabin BA, Griffin JW, Crain BJ, Scavina M, Chance PF, Cornblath DR. Autosomal dominant juvenile amyotrophic lateral sclerosis. Brain. 1999;122(Pt 8):1539–50.PubMedView ArticleGoogle Scholar
  36. Saiga T, Tateishi T, Torii T, Kawamura N, Nagara Y, Shigeto H, et al. Inflammatory radiculoneuropathy in an ALS4 patient with a novel SETX mutation. J Neurol Neurosurg Psychiatry. 2012;83:763–4.PubMedView ArticleGoogle Scholar
  37. Zhao ZH, Chen WZ, Wu ZY, Wang N, Zhao GX, Chen WJ, et al. A novel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:118–22.PubMedView ArticleGoogle Scholar
  38. Chen YZ, Hashemi SH, Anderson SK, Huang Y, Moreira MC, Lynch DR, et al. Senataxin, the yeast Sen1p orthologue: characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease. Neurobiol Dis. 2006;23:97–108.PubMedView ArticleGoogle Scholar
  39. Moreira MC, Klur S, Watanabe M, Nemeth AH, Le Ber I, Moniz JC, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet. 2004;36:225–7.PubMedView ArticleGoogle Scholar
  40. Orlacchio A, Babalini C, Borreca A, Patrono C, Massa R, Basaran S, et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain. 2010;133:591–8.PubMed CentralPubMedView ArticleGoogle Scholar
  41. Iguchi Y, Katsuno M, Ikenaka K, Ishigaki S, Sobue G. Amyotrophic lateral sclerosis: an update on recent genetic insights. J Neurol. 2013;260:2917–27.PubMedView ArticleGoogle Scholar
  42. Paisan-Ruiz C, Dogu O, Yilmaz A, Houlden H, Singleton A. SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia. Neurology. 2008;70:1384–9.PubMed CentralPubMedView ArticleGoogle Scholar
  43. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 2012;1462:3–15.PubMed CentralPubMedView ArticleGoogle Scholar
  44. Boylan K. Familial Amyotrophic Lateral Sclerosis. Neurol Clin. 2015;33:807–30.PubMedView ArticleGoogle Scholar
  45. Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol. 2014;10:337–48.PubMedView ArticleGoogle Scholar
  46. Yan J, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology. 2010;75:807–14.PubMed CentralPubMedView ArticleGoogle Scholar
  47. Baumer D, Hilton D, Paine SM, Turner MR, Lowe J, Talbot K, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology. 2010;75:611–8.PubMed CentralPubMedView ArticleGoogle Scholar
  48. Munoz DG. FUS mutations in sporadic juvenile ALS: another step toward understanding ALS pathogenesis. Neurology. 2010;75:584–5.PubMedView ArticleGoogle Scholar
  49. Merner ND, Girard SL, Catoire H, Bourassa CV, Belzil VV, Riviere JB, et al. Exome sequencing identifies FUS mutations as a cause of essential tremor. Am J Hum Genet. 2012;91:313–9.PubMed CentralPubMedView ArticleGoogle Scholar
  50. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:822–31.PubMed CentralPubMedView ArticleGoogle Scholar
  51. van Es MA, Diekstra FP, Veldink JH, Baas F, Bourque PR, Schelhaas HJ, et al. A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. Neurology. 2009;72:287–8.PubMedView ArticleGoogle Scholar
  52. Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J Med Genet. 2010;47:554–60.PubMedView ArticleGoogle Scholar
  53. Luigetti M, Lattante S, Zollino M, Conte A, Marangi G, Del Grande A, et al. SOD1 G93D sporadic amyotrophic lateral sclerosis (SALS) patient with rapid progression and concomitant novel ANG variant. Neurobiol Aging. 2011;1924(32):e15–8.Google Scholar
  54. Gellera C, Colombrita C, Ticozzi N, Castellotti B, Bragato C, Ratti A, et al. Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. Neurogenetics. 2008;9:33–40.PubMedView ArticleGoogle Scholar
  55. Seilhean D, Cazeneuve C, Thuries V, Russaouen O, Millecamps S, Salachas F, et al. Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation. Acta Neuropathol. 2009;118:561–73.PubMedView ArticleGoogle Scholar
  56. van Es MA, Schelhaas HJ, van Vught PW, Ticozzi N, Andersen PM, Groen EJ, et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol. 2011;70:964–73.PubMedView ArticleGoogle Scholar
  57. Millecamps S, Boillee S, Le Ber I, Seilhean D, Teyssou E, Giraudeau M, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet. 2012;49:258–63.PubMedView ArticleGoogle Scholar
  58. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995–1007.PubMedView ArticleGoogle Scholar
  59. Chio A, Borghero G, Pugliatti M, Ticca A, Calvo A, Moglia C, et al. Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. Arch Neurol. 2011;68:594–8.PubMed CentralPubMedView ArticleGoogle Scholar
  60. Kirby J, Goodall EF, Smith W, Highley JR, Masanzu R, Hartley JA, et al. Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis. Neurogenetics. 2010;11:217–25.PubMedView ArticleGoogle Scholar
  61. Corcia P, Valdmanis P, Millecamps S, Lionnet C, Blasco H, Mouzat K, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78:1519–26.PubMedView ArticleGoogle Scholar
  62. Xiong HL, Wang JY, Sun YM, Wu JJ, Chen Y, Qiao K, et al. Association between novel TARDBP mutations and Chinese patients with amyotrophic lateral sclerosis. BMC Med Genet. 2010;11:8.PubMed CentralPubMedView ArticleGoogle Scholar
  63. Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M, et al. TARDBP 3′-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol. 2009;118:633–45.PubMed CentralPubMedView ArticleGoogle Scholar
  64. Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol. 2009;65:470–3.PubMedView ArticleGoogle Scholar
  65. Origone P, Caponnetto C, Bandettini Di Poggio M, Ghiglione E, Bellone E, Ferrandes G, et al. Enlarging clinical spectrum of FALS with TARDBP gene mutations: S393L variant in an Italian family showing phenotypic variability and relevance for genetic counselling. Amyotroph Lateral Scler. 2010;11:223–7.PubMedView ArticleGoogle Scholar
  66. Quadri M, Cossu G, Saddi V, Simons EJ, Murgia D, Melis M, et al. Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson’s disease in Sardinia. Neurogenetics. 2011;12:203–9.PubMed CentralPubMedView ArticleGoogle Scholar
  67. Rayaprolu S, Fujioka S, Traynor S, Soto-Ortolaza AI, Petrucelli L, Dickson DW, et al. TARDBP mutations in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:312–5.PubMed CentralPubMedView ArticleGoogle Scholar
  68. Chow CY, Zhang Y, Dowling JJ, Jin N, Adamska M, Shiga K, et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature. 2007;448:68–72.PubMed CentralPubMedView ArticleGoogle Scholar
  69. Chow CY, Landers JE, Bergren SK, Sapp PC, Grant AE, Jones JM, et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet. 2009;84:85–8.PubMed CentralPubMedView ArticleGoogle Scholar
  70. Campeau PM, Lenk GM, Lu JT, Bae Y, Burrage L, Turnpenny P, et al. Yunis-Varon syndrome is caused by mutations in FIG4, encoding a phosphoinositide phosphatase. Am J Hum Genet. 2013;92:781–91.PubMed CentralPubMedView ArticleGoogle Scholar
  71. Baulac S, Lenk GM, Dufresnois B, Ouled Amar Bencheikh B, Couarch P, Renard J, et al. Role of the phosphoinositide phosphatase FIG4 gene in familial epilepsy with polymicrogyria. Neurology. 2014;82:1068–75.PubMed CentralPubMedView ArticleGoogle Scholar
  72. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295:1077–9.PubMedView ArticleGoogle Scholar
  73. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223–6.PubMedView ArticleGoogle Scholar
  74. Iida A, Hosono N, Sano M, Kamei T, Oshima S, Tokuda T, et al. Novel deletion mutations of OPTN in amyotrophic lateral sclerosis in Japanese. Neurobiol Aging. 2012;1843(33):e19–24.Google Scholar
  75. Johnson L, Miller JW, Gkazi AS, Vance C, Topp SD, Newhouse SJ, et al. Screening for OPTN mutations in a cohort of British amyotrophic lateral sclerosis patients. Neurobiol Aging. 2012;33:2948. e15-7.PubMedView ArticleGoogle Scholar
  76. Millecamps S, Boillee S, Chabrol E, Camu W, Cazeneuve C, Salachas F, et al. Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiol Aging. 2011;32:557. e11-3.PubMedView ArticleGoogle Scholar
  77. Kamada M, Izumi Y, Ayaki T, Nakamura M, Kagawa S, Kudo E, et al. Clinicopathologic features of autosomal recessive amyotrophic lateral sclerosis associated with optineurin mutation. Neuropathology. 2014;34:64–70.PubMedView ArticleGoogle Scholar
  78. Weishaupt JH, Waibel S, Birve A, Volk AE, Mayer B, Meyer T, et al. A novel optineurin truncating mutation and three glaucoma-associated missense variants in patients with familial amyotrophic lateral sclerosis in Germany. Neurobiol Aging. 2013;34:1516. e9-15.PubMedView ArticleGoogle Scholar
  79. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14:285–91.PubMedView ArticleGoogle Scholar
  80. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069–75.PubMed CentralPubMedView ArticleGoogle Scholar
  81. Liu X, Lu M, Tang L, Zhang N, Chui D, Fan D. ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2013;34:2236. e5-8.PubMedGoogle Scholar
  82. Lu HP, Gan SR, Chen S, Li HF, Liu ZJ, Ni W, et al. Intermediate-length polyglutamine in ATXN2 is a possible risk factor among Eastern Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2014;36:1603.PubMedGoogle Scholar
  83. Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW, Thijs V, et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology. 2011;76:2066–72.PubMedView ArticleGoogle Scholar
  84. Infante J, Berciano J, Volpini V, Corral J, Polo JM, Pascual J, et al. Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease. Mov Disord. 2004;19:848–52.PubMedView ArticleGoogle Scholar
  85. Nanetti L, Fancellu R, Tomasello C, Gellera C, Pareyson D, Mariotti C. Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. J Neurol. 2009;256:1926–8.PubMedView ArticleGoogle Scholar
  86. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377–81.PubMedView ArticleGoogle Scholar
  87. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857–64.PubMed CentralPubMedView ArticleGoogle Scholar
  88. Gonzalez-Perez P, Cirulli ET, Drory VE, Dabby R, Nisipeanu P, Carasso RL, et al. Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. Neurology. 2012;79:2201–8.PubMed CentralPubMedView ArticleGoogle Scholar
  89. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211–5.PubMed CentralPubMedView ArticleGoogle Scholar
  90. Millecamps S, Corcia P, Cazeneuve C, Boillee S, Seilhean D, Danel-Brunaud V, et al. Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:839. e1-3.PubMedView ArticleGoogle Scholar
  91. Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70:913–9.PubMedView ArticleGoogle Scholar
  92. Belzil VV, Daoud H, Camu W, Strong MJ, Dion PA, Rouleau GA. Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. Eur J Hum Genet. 2013;21:237–9.PubMed CentralPubMedView ArticleGoogle Scholar
  93. Li X, Hu Z, Liu L, Xie Y, Zhan Y, Zi X, et al. A SIGMAR1 splice-site mutation causes distal hereditary motor neuropathy. Neurology. 2015;84:2430–7.PubMedView ArticleGoogle Scholar
  94. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005;37:806–8.PubMedView ArticleGoogle Scholar
  95. Cox LE, Ferraiuolo L, Goodall EF, Heath PR, Higginbottom A, Mortiboys H, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One. 2010;5:e9872.PubMed CentralPubMedView ArticleGoogle Scholar
  96. van Blitterswijk M, Vlam L, van Es MA, van der Pol WL, Hennekam EA, Dooijes D, et al. Genetic overlap between apparently sporadic motor neuron diseases. PLoS One. 2012;7:e48983.PubMed CentralPubMedView ArticleGoogle Scholar
  97. Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499–503.PubMed CentralPubMedView ArticleGoogle Scholar
  98. Daoud H, Dobrzeniecka S, Camu W, Meininger V, Dupre N, Dion PA, et al. Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiol Aging. 2013;34:1311. e1-2.PubMedGoogle Scholar
  99. Ingre C, Landers JE, Rizik N, Volk AE, Akimoto C, Birve A, et al. A novel phosphorylation site mutation in profilin 1 revealed in a large screen of US, Nordic, and German amyotrophic lateral sclerosis/frontotemporal dementia cohorts. Neurobiol Aging. 2013;1708(34):e1–6.Google Scholar
  100. Lattante S, Le Ber I, Camuzat A, Brice A, Kabashi E. Mutations in the PFN1 gene are not a common cause in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration in France. Neurobiol Aging. 2013;1709(34):e1–2.Google Scholar
  101. Smith BN, Vance C, Scotter EL, Troakes C, Wong CH, Topp S, et al. Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiol Aging. 2015;1602(36):e17–27.Google Scholar
  102. Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, et al. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013;93:900–5.PubMed CentralPubMedView ArticleGoogle Scholar
  103. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467–73.PubMed CentralPubMedView ArticleGoogle Scholar
  104. Seelen M, Visser AE, Overste DJ, Kim HJ, Palud A, Wong TH, et al. No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. Neurobiol Aging. 2014;35:1956. e9-56 e11.PubMedView ArticleGoogle Scholar
  105. Le Ber I, Van Bortel I, Nicolas G, Bouya-Ahmed K, Camuzat A, Wallon D, et al. hnRNPA2B1 and hnRNPA1 mutations are rare in patients with “multisystem proteinopathy” and frontotemporal lobar degeneration phenotypes. Neurobiol Aging. 2014;35:934. e5-6.PubMedGoogle Scholar
  106. Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17:664–6.PubMed CentralPubMedView ArticleGoogle Scholar
  107. Lin KP, Tsai PC, Liao YC, Chen WT, Tsai CP, Soong BW, et al. Mutational analysis of MATR3 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2005;2015(36):e1–4.Google Scholar
  108. Leblond CS, Gan-Or Z, Spiegelman D, Laurent SB, Szuto A, Hodgkinson A, et al. Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015;37:209.PubMedGoogle Scholar
  109. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.PubMed CentralPubMedView ArticleGoogle Scholar
  110. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68.PubMed CentralPubMedView ArticleGoogle Scholar
  111. Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, Johnson L, et al. The C9ORF72 expansion mutation is a common cause of ALS+/−FTD in Europe and has a single founder. Eur J Hum Genet. 2013;21:102–8.PubMed CentralPubMedView ArticleGoogle Scholar
  112. Rutherford NJ, Heckman MG, Dejesus-Hernandez M, Baker MC, Soto-Ortolaza AI, Rayaprolu S, et al. Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging. 2012;33:2950. e5-7.PubMed CentralPubMedGoogle Scholar
  113. Majounie E, Abramzon Y, Renton AE, Perry R, Bassett SS, Pletnikova O, et al. Repeat expansion in C9ORF72 in Alzheimer’s disease. N Engl J Med. 2012;366:283–4.PubMed CentralPubMedView ArticleGoogle Scholar
  114. Hensman Moss DJ, Poulter M, Beck J, Hehir J, Polke JM, Campbell T, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology. 2014;82:292–9.PubMed CentralPubMedView ArticleGoogle Scholar
  115. Lesage S, Le Ber I, Condroyer C, Broussolle E, Gabelle A, Thobois S, et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain. 2013;136:385–91.PubMed CentralPubMedView ArticleGoogle Scholar
  116. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, et al. Mutant dynactin in motor neuron disease. Nat Genet. 2003;33:455–6.PubMedView ArticleGoogle Scholar
  117. Liu ZJ, Li HF, Tan GH, Tao QQ, Ni W, Cheng XW, et al. Identify mutation in amyotrophic lateral sclerosis cases using HaloPlex target enrichment system. Neurobiol Aging. 2014;35:2881. e11-5.PubMedGoogle Scholar
  118. Munch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ, et al. Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol. 2005;58:777–80.PubMedView ArticleGoogle Scholar
  119. Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, Stoessl AJ, Grantier LL, et al. DCTN1 mutations in Perry syndrome. Nat Genet. 2009;41:163–5.PubMed CentralPubMedView ArticleGoogle Scholar
  120. Araki E, Tsuboi Y, Daechsel J, Milnerwood A, Vilarino-Guell C, Fujii N, et al. A novel DCTN1 mutation with late-onset parkinsonism and frontotemporal atrophy. Mov Disord. 2014;29:1201–4.PubMedView ArticleGoogle Scholar
  121. Caroppo P, Le Ber I, Clot F, Rivaud-Pechoux S, Camuzat A, De Septenville A, et al. DCTN1 mutation analysis in families with progressive supranuclear palsy-like phenotypes. JAMA Neurol. 2014;71:208–15.PubMedView ArticleGoogle Scholar
  122. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70:1582–8.PubMed CentralPubMedView ArticleGoogle Scholar
  123. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68:1440–6.PubMedView ArticleGoogle Scholar
  124. Hirano M, Nakamura Y, Saigoh K, Sakamoto H, Ueno S, Isono C, et al. Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology. 2013;80:458–63.PubMedView ArticleGoogle Scholar
  125. Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology. 2012;79:1556–62.PubMed CentralPubMedView ArticleGoogle Scholar
  126. Chen Y, Zheng ZZ, Chen X, Huang R, Yang Y, Yuan L, et al. SQSTM1 mutations in Han Chinese populations with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2014;35:726. e7-9.PubMedGoogle Scholar


© Li and Wu. 2016